CTOs on the Move

Intouch Solutions

www.intouchsol.com

 
At Intouch Solutions, we know pharma marketing isn`t easy. But after more than a decade of hard work in this and similarly regulated industries, we think we understand that better than most. We have a pretty good idea of what it takes to connect your customers to your brand.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.intouchsol.com
  • 7045 College Blvd. Suite 300
    Overland Park, KS USA 66211
  • Phone: 913.317.9700

Executives

Name Title Contact Details

Similar Companies

Madrigal Pharmaceuticals

Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. The Company has advanced its lead candidate, resmetirom, also known as MGL-3196, a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) β-selective agonist, through Phase 2 clinical trials in NASH. Primary and key secondary endpoints were achieved including reduction of liver fat on a sensitive non-invasive imaging test, lowering of multiple atherogenic lipids including LDL-cholesterol and triglycerides, and resolution of NASH on liver biopsy. Based on evidence of broad activity and a favorable safety profile, Madrigal has initiated a Phase 3 clinical study in NASH patients with advanced liver fibrosis, MAESTRO-NASH, in which the primary endpoint after one year of dosing is resolution of NASH and key secondary endpoints include LDL-cholesterol lowering and reduction in liver fibrosis. Clinical benefit in reducing progression to more advanced liver disease, including cirrhosis, is a long-term goal of this trial. A second Phase 3 clinical study, MAESTRO-NAFLD-1, has also been initiated. This 52-week non-invasive study in a broader segment of NASH patients will provide additional safety information to support the NASH indication and will include key efficacy endpoints: LDL-cholesterol lowering, triglyceride lowering, reduction of liver fat as determined by MRI-PDFF, as well as reduction of elevated liver enzymes and reduction in fibrosis biomarkers. This is a non-biopsy study in people with NASH, as documented using non-invasive techniques or historical liver biopsy.

Corktown Health

Moderna COVID-19 Vaccine Clinic and Health Fair Let’s do our part! Corktown Health is offering the Moderna COVID-19 vaccine on 5/21, 5/28, 6/1, 6/4, and 6/5 from 8:30am to 1pm. We will also be offering vaccines at the Hazel Park Recreation Center on 6/...

Integrated Nano-Technologies

Integrated Nano-Technologies is a Henrietta, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Phagetech

Phagetech is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Headstrong Project

Headstrong provides cost-free, barrier-free, stigma-free mental health treatment for veterans and their families.